Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INN-MS: Ocrelizumab Effect on Microglial Activation
NCT03691077Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2018
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Decrease in the extent of brain white matter microglial activation at 24 months. Status: unknown.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT03691077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691077.